Trusted Resources: Education
Scientific literature and patient education texts
Cell-Penetrating Peptide-Conjugated Morpholino Rescues SMA in a Symptomatic Preclinical Model
source: Molecular therapy : the journal of the American Society of Gene Therapy
year: 2021
authors: Bersani M,Rizzuti M,Pagliari E,Garbellini M,Saccomanno D,Moulton HM,Bresolin N,Comi GP,Corti S,Nizzardo M
summary/abstract:Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of infant mortality. Recently approved SMA therapies have transformed a deadly disease into a survivable one, but these compounds show a wide spectrum of clinical response and effective rescue only in the early stages of the disease. Therefore, safe, symptomatic-suitable, non-invasive treatments with high clinical impact across different phenotypes are urgently needed. We conjugated antisense oligonucleotides with Morpholino (MO) chemistry, which increase SMN protein levels, to cell-penetrating peptides (CPPs) for better cellular distribution. Systemically administered MOs linked to r6 and (RXRRBR)XB peptides crossed the blood-brain barrier and increased SMN protein levels remarkably, causing striking improvement of survival, neuromuscular function, and neuropathology, even in symptomatic SMA animals. Our study demonstrates that MO-CPP conjugates can significantly expand the therapeutic window through minimally invasive systemic administration, opening the path for clinical applications of this strategy.
organization: Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy.DOI: 10.1016/j.ymthe.2021.11.012
read more
Related Content
-
New Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...
-
What It Is Like to Have a Rare Disease. How Clinical Trials Changed My Life?When I was about 1, I started walking wi...
-
The SMA France National Registry: Already Encouraging ResultsSpinal muscular atrophy is a debilitatin...
-
Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiat...Spinal muscular atrophy (SMA) is an auto...
-
An Interview With Muscular Dystrophy Association President Donald S. WoodLarry Luxner, senior correspondent for R...
-
Missense Mutation in Gene Caused Psychomotor Developmental Delay and Muscle Weakness: A Case ReportThe gene encodes a part of the dynamic p...
-
Why Some Drugs Cost $2.1 Million per Dose and how one Company Plans to Change ThisWith a cost of $2.1 million for a one-do...